Alzheimer’s disease treatment has entered a new chapter, but important gaps remain. Drugs that remove amyloid can slow decline in selected patients with early disease. They do not stop Alzheimer’s or restore lost cognitive function. That leaves a question worth exploring: could treatments that support brain signaling and circulation complement amyloid removal?
PDE5 inhibitors, including sildenafil, tadalafil, and the investigational drug AR1001, are attracting attention. They are not established Alzheimer’s treatments. Observational associations and laboratory findings provide reasons to investigate them, but do not prove that they prevent dementia or slow its progression.
My view is that this research deserves serious attention because Alzheimer’s involves more than amyloid. The opportunity may lie in addressing several interacting processes, provided clinical trials demonstrate meaningful benefits.
What You’ll Learn
- What antiamyloid treatments have achieved and where their limitations remain.
- Why PDE5 inhibitors are being investigated for Alzheimer’s disease.
- What sildenafil studies and AR1001 trials actually show.
- Why combination therapy is an interesting, unproven possibility.
What Current Alzheimer’s Disease Treatments Can Achieve
Lecanemab, sold as Leqembi, and donanemab, sold as Kisunla, target amyloid, a protein that accumulates in Alzheimer’s disease. Their trials demonstrated slower decline in selected patients with early disease, rather than a reversal of dementia.
In CLARITY AD, lecanemab reduced worsening on the Clinical Dementia Rating Sum of Boxes, or CDR SB, by approximately 27% relative to placebo over 18 months. The absolute difference was 0.45 points: scores worsened by 1.21 points with lecanemab and 1.66 with placebo. The percentage describes relative slowing on that measure, not a 27% improvement in memory.
In TRAILBLAZER ALZ 2, donanemab slowed decline by approximately 22% on the integrated Alzheimer’s Disease Rating Scale and 29% on CDR SB in the combined population. Effects differed by outcome and tau burden. These separate trials do not establish which drug is better.
I regard these findings as an important advance, although the benefit an individual experiences must be weighed against treatment risks and burden. Slower decline matters, but it leaves substantial unmet needs. Those needs explain the interest in approaches beyond amyloid.
Why Amyloid Removal Leaves Important Treatment Gaps
These treatments are used in early Alzheimer’s disease, with treatment initiated at the mild cognitive impairment or mild dementia stage and amyloid pathology confirmed. Their suitability requires an individual assessment. The FDA’s Kisunla overview describes this population and the associated imaging risks.
Both antibodies can cause amyloid-related imaging abnormalities, or ARIA, including brain swelling and small areas of bleeding. The Leqembi prescribing information identifies higher ARIA risk in APOE ε4 homozygotes and calls for MRI monitoring. Bleeding risk and anticoagulant use also require careful consideration.
Alzheimer’s additionally involves tau abnormalities, inflammation, vascular changes, metabolic stress, and disruption of connections between neurons. My interpretation is that removing one source of injury may not fully address the conditions that make brain cells vulnerable.
This does not diminish the evidence for amyloid treatment. It supports asking whether other mechanisms can deliver additional benefit, which brings PDE5 signaling into the discussion.
How PDE5 Inhibitors Might Affect Brain Signaling
PDE5 is an enzyme that breaks down cyclic guanosine monophosphate, or cGMP. This signaling molecule participates in vascular function and cellular communication. Blocking PDE5 allows cGMP signaling to persist longer, providing a biological rationale for studying effects beyond erectile dysfunction and pulmonary hypertension.
In preclinical research on mirodenafil, investigators reported effects involving the cGMP, protein kinase G, and CREB pathway. CREB helps regulate genes involved in neuronal survival and memory related processes. BDNF, a protein that supports neurons and their connections, is another part of this rationale.
The same cell and mouse experiments reported effects on amyloid, phosphorylated tau, mitochondrial function, and other signaling pathways. These findings suggest several possible actions. They do not establish that the same effects occur to a clinically meaningful degree in people with Alzheimer’s.
In my view, that breadth makes PDE5 inhibition interesting. It also creates a demanding test: a plausible mechanism must translate into preserved cognition or daily function. Human studies provide the next layer of evidence.
Sildenafil and Alzheimer’s: What Human Studies Show
A 2021 study combining network analysis, insurance records, and laboratory experiments examined data covering more than seven million people. Sildenafil use was associated with a 69% lower incidence of Alzheimer’s disease. That was an observational association, not a measured treatment effect from a randomized prevention trial.
A 2024 cohort study followed 269,725 men with erectile dysfunction. Starting a PDE5 inhibitor was associated with an 18% lower adjusted risk of Alzheimer’s disease. Prescription records cannot establish exactly how much medication people took, and the population limits how broadly the findings can be applied.
The evidence is mixed. A Medicare analysis of patients with pulmonary hypertension found no evidence of reduced Alzheimer’s disease and related dementia risk compared with another treatment for the same condition. Differences in health, prescribing, and study design may contribute to the conflicting results.
A separate small physiological study found increased cerebral blood flow and oxygen metabolism after a single sildenafil dose. It did not establish lasting cognitive benefit. My assessment is that these signals justify trials, while lower diagnosis rates and improved circulation remain different outcomes from slowing established Alzheimer’s disease. AR1001 is being tested more directly against that clinical question.
AR1001: What the Phase 2 Trial Actually Found
AR1001, also known as mirodenafil, is an oral PDE5 inhibitor being developed by AriBio for Alzheimer’s disease. Its preclinical findings raise the possibility of effects across several disease related pathways, but human efficacy requires separate evidence.
The published Phase 2 trial enrolled 210 participants with mild to moderate Alzheimer’s disease. It did not meet its primary cognitive or global clinical endpoints at 26 weeks. That result belongs at the center of any fair account of the program.
Participants receiving 30 mg showed favorable changes in plasma p tau181, p tau217, and GFAP compared with placebo. These biomarkers relate to Alzheimer’s pathology and glial activity. Their movement does not, by itself, demonstrate improved memory or daily functioning. Treatment was generally well tolerated within this study.
Earlier sponsor reports also highlighted an encouraging cognitive signal in participants receiving AR1001 without other Alzheimer’s medications. Such subgroup findings need caution and cannot replace a successful primary endpoint. My view remains cautiously interested: the biology warrants a larger test, but the Phase 2 results do not prove disease modification. That is the role of the Phase 3 program.
POLARIS AD: The Phase 3 Test and Current Evidence
The POLARIS AD trial, NCT05531526, evaluates AR1001 against placebo in early Alzheimer’s disease. Its main study compares once-daily treatment over 52 weeks, with CDR SB as the primary clinical outcome.
In an August 3, 2026 announcement, AriBio reported 1,535 enrolled participants and 1,348 who completed the 52 week dosing period. Enrollment and treatment completion should not be treated as interchangeable numbers.
That announcement stated that the main treatment phase was complete and topline results were expected in the fourth quarter of 2026, with detailed findings planned for CTAD 2026. This is a sponsor reported timeline, not an efficacy result. The article’s timing information is based on sources checked October 14, 2026.
The following comparison highlights why these drugs should not be discussed as though they have equivalent evidence. It also provides context for considering future treatment options.
| Drug | Evidence discussed here | What remains unproven |
|---|---|---|
| Sildenafil, including Viagra | Observational associations, laboratory findings, and small physiological studies | Prevention of Alzheimer’s or slower clinical progression |
| Tadalafil | Included in some PDE5 class analyses; much less direct Alzheimer’s specific evidence in this discussion | A reliable clinical benefit for Alzheimer’s disease |
| AR1001, mirodenafil | Phase 2 missed primary endpoints but showed biomarker changes; Phase 3 program underway through analysis | Clinically meaningful efficacy and suitability for routine treatment |
Could PDE5 Inhibitors Help Patients Unsuitable for Amyloid Therapy?
An effective oral treatment with a different mechanism could eventually expand options for people unable to receive amyloid antibodies. That possibility is especially relevant when bleeding concerns, monitoring requirements, or practical circumstances complicate antibody treatment.
Because PDE5 inhibitors do not clear amyloid through the same antibody mechanism, their risk profile may differ. However, it would be premature to assume they are safe substitutes for patients with cerebral microhemorrhages, suspected amyloid angiopathy, or anticoagulant use. That requires evidence in the relevant populations.
Conventional PDE5 inhibitors also carry their own precautions. For example, sildenafil prescribing information contraindicates use with nitrates because of potentially dangerous blood pressure reductions and identifies interactions with other medicines.
My view is that a different mechanism could be valuable, provided efficacy and safety are demonstrated. Neither convenience nor the absence of antibody-mediated amyloid clearance establishes a favorable benefit-to-risk balance. The broader possibility is whether complementary treatments could work together.
Why Combination Therapy Deserves Investigation
Perhaps the most interesting future is PDE5 inhibition alongside amyloid treatment. One approach removes a pathological protein, while another might support signaling, circulation, or neuronal resilience. This is a hypothesis about complementary mechanisms.
The writer’s central perspective remains: Alzheimer’s is a complex disorder, and a single target may not address every process contributing to decline. Reducing pathological burden while improving the conditions in which neurons function is a compelling research direction.
The sources reviewed here do not establish that sildenafil, tadalafil, or AR1001 adds benefit to lecanemab or donanemab. Dedicated combination trials would need to demonstrate both efficacy and safety rather than assuming the drugs’ effects are additive.
I consider that distinction essential. A promising concept deserves testing, not automatic adoption. The practical questions below help separate that research interest from present treatment decisions.
Frequently Asked Questions About PDE5 Inhibitors and Alzheimer’s
1. Is sildenafil an established Alzheimer’s treatment?
No. The research discussed here does not establish sildenafil as a treatment that slows Alzheimer’s progression. Observational associations cannot demonstrate that taking it prevents dementia.
2. Is AR1001 the same drug as Viagra?
No. AR1001 is mirodenafil; Viagra contains sildenafil. Both inhibit PDE5, but evidence for one compound cannot automatically be transferred to another.
3. Did AR1001 succeed in its Phase 2 trial?
It did not meet its primary clinical endpoints at 26 weeks. Favorable biomarker findings supported further investigation but did not establish a clinical treatment benefit.
4. When are POLARIS AD results expected?
AriBio’s August 2026 announcement projected topline results in the fourth quarter of 2026. Readers should check the trial registry and subsequent publications for updates.
These distinctions frame the question that future results must answer: can PDE5 inhibition deliver benefits patients actually experience?
Looking Ahead: A Broader Approach to Alzheimer’s Disease Treatment
PDE5 inhibitors are credible research candidates, but their role in Alzheimer’s disease treatment remains unproven. Sildenafil associations, AR1001 biomarker findings, and experimental mechanisms each contribute evidence without settling the clinical question.
A positive Phase 3 result would strengthen the case for AR1001 specifically. It would not automatically prove that sildenafil or tadalafil works similarly. A negative result would still help clarify whether the compound, disease stage, or therapeutic approach needs reconsideration.
Our perspective is that the next generation of treatment may need to do more than remove harmful proteins. Supporting the signaling, circulation, energy production, and plasticity that allow neurons to function could become part of a broader strategy, if clinical trials support it.
At Sharlin Health and Neurology, we help patients and families understand their neurological concerns and explore care options based on their individual needs. If you are concerned about memory changes or have questions about Alzheimer’s disease treatment, contact our team to schedule a consultation. We can discuss your concerns and help you understand the next steps in your care.
